Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 42(3); 2010 > Article
Review Article RNA Regulation in Neurologic Disease and Cancer
Robert B. Darnell, M.D., Ph.D.
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2010;42(3):125-129.
DOI: https://doi.org/10.4143/crt.2010.42.3.125
Published online: September 30, 2010

Howard Hughes Medical Institute, Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, NY, USA.

Correspondence: Robert B. Darnell, M.D., Ph.D. Laboratory of Molecular Neuro-Oncology, The Rockefeller University, Box 226, 1230 York Avenue, New York, NY 10021, USA.
Tel: 1-212-327-7460, Fax: 1-212-327-7109, darnelr@rockefeller.edu
• Received: August 18, 2010   • Accepted: August 20, 2010

Copyright © 2010 by Korean Cancer Association

  • 13,741 Views
  • 107 Download
  • 28 Crossref
next
Full Article

Download PDF Download PDF

  • The paraneoplastic neurologic diseases (PNDs) are brain degenerations that develop in the setting of clinically inapparent cancers. PNDs arise when common cancers express brain proteins, triggering an anti-tumor immune response and tumor immunity. Research on these brain-cancer proteins has revealed a new world of neuron-specific RNA binding proteins whose functions may be aberrantly used by tumor cells. Efforts to gain insight into their function has led to the development of new methods and strategies to understand RNA protein regulation in living tissues.
  • Key words: Paraneoplastic neurologic degeneration, Nova, RNA binding protein, CLIP, Tumor immunity
The paraneoplastic neurologic degenerations (PNDs) are a set of brain disorders that develop in the setting of occult cancer (Table 1). These disorders arise when common cancers express brain proteins, triggering an anti-tumor immune response and, at least in some cases, clinically effective suppression of the malignancy. PNDs come to clinical attention only when the tumor immune response breaches immune privilege of the nervous system, and begins to attack the neurons that are normally expressing the tumor antigen (which we have termed onconeural antigens). Our laboratory first demonstrated that genes encoding onconeural antigens can be cloned using high titer antisera from these patients (1-5), and currently over a dozen well-described PND antigens have been defined.
cDNAs encoding PND antigens have provided a wealth of information regarding the nature of the PND antigens (6-8) as well as their role in disease pathogenesis (9-11). For example, the initial cloning of a cerebellar antigen from a woman with presumed ovarian cancer led to the discovery of a long-suspected neuronspecific vesicle coat protein (4). Cloning of the cerebellar antigen (cdr2) associated more commonly with gynecologic cancer revealed the presence of antigen-specific T cells in these patients, establishing a cellmediated component to the disorders, as well as a means by which tumor antigen is likely cross-presented from apoptotic cells to dendritic cells to initiate the anti-tumor immune response (12,13). These studies have led to clinical cancer vaccine trials in prostate cancer patients that have shown some evidence of efficacy in Phase I safety studies (14). Moreover, cloning of the genes encoding T cell receptors from these patients offers a possible new therapeutic strategy, by passive transfer of these genes into T cells to induce tumor-cell targeting (15).
Among the set of cloned PND antigens, perhaps none has generated as much biologic interest as the Nova and Elavl (Hu) family of neuronspecific RNA binding proteins. The Nova proteins (16,17) are ectopically expressed in lung or gynecologic cancers, and trigger neurologic symptoms (excess motor movements of the eyes and musculature) interpreted by neurologists as failure of inhibitory motor control. Studies of the Nova proteins have established what is arguably the best data available to understand a tissue-specific RNA regulatory protein in the brain; these findings will be discussed here. The Elavl proteins (originally termed the Hu proteins; (18,19) are still incompletely understood (6,20), but are believed to relate to post-transcriptional regulation of RNA in the brain. Many of the approaches used to understand the biology of Nova can be applied more generally-to the understanding of the biology of the Elavl proteins and other RNA binding proteins in the brain and cancer.
Understanding RBP function requires understanding the protein's interaction with RNA. Nova has emerged as one of the best understood mammalian RNA binding proteins in part because there is a good understanding of its RNA substrates. After recognizing that Nova harbors three KH-type RNA binding proteins (21), in vitro RNA selection experiments (22,23) were applied to reveal (17,24) that Nova recognizes a core 4 nucleotide repeat sequence-(UCAU)3. Mutagenesis and X-Ray crystallographic studies identified the CA dinucleotide as a critical invariant component of Nova-RNA binding (25,26), with specificity restricted to bounding pyrimidines, hence the more general consensus of YCAY repeats as the core binding motif.
These studies prompted a search for brain transcripts harboring such repeat elements. This relatively pedestrian approach yielded three targets, which were characterized by mutagenesis, boundary mapping, and functional analyses in some detail. The first target transcript harboring a Nova-regulated YCAY cluster was the inhibitory glycine receptor α2 (GlyRα2). Interestingly, this cluster was located within an intronic sequence upstream of an alternatively spliced exon (E3A) of GlyRα2. Analysis of alternative splicing of minigenes transfected into tissue culture cells demonstrated that Nova acted specifically on the YCAY cluster to mediate an increase in inclusion of E3A (24). Subsequently, analogous studies demonstrated that Nova was able to bind intronic YCAY elements to mediate an increase in the γ2L exon of the GABAA transcript (27), and to bind exonic and intronic YCAY elements to autoinhibit splicing of Nova1 exon 4 (28). This led to the hypothesis that Nova might regulate alternative splicing of these and other transcripts in neurons.
This hypothesis was tested in vivo by generating Nova null mice. GlyRγ2 E3A and GABAA γ2L splicing showed consistent two and three-fold decreases in utilization, respectively, in Nova1 KO mice (25), while Nova E4 exclusion was decreased -0.75-fold in Nova1 heterozygous mice (28). These studies established Nova as the first bona-fide mammalian tissue specific splicing factor whose actions were validated in live animals, and set the stage for more global studies of Nova function. These were further stimulated by recognizing the correlation between Nova targeting in PND patients, who show defects in inhibitory motor control, and the observation that 2/2 Nova-regulated transcripts encoded inhibitory neurotransmitter receptors (29).
Initial studies aimed at discovering the general nature of Nova action on alternative splicing were done using a new (at the time) Affymetrix exon junction array. Applying WT or Nova KO RNA to these arrays, whose probesets were designed to detect alternative splice junctions, revealed a wealth of new target transcripts that could be independently validated as Nova targets in vivo. Most surprisingly, the results revealed that the vast majority of Nova-regulated transcripts encoded synaptic proteins. More precisely, the steady-state level of these regulated RNAs was unaltered in Nova null mouse brain, but their quality manifest by different ratios of alternative exons-was altered (30).
A limitation of this work came from careful parsing of the term Nova-regulated transcripts. These transcripts showed Nova-dependent changes in alternative splicing, but such changes might be a direct action of Nova-for example, acting on YCAY elements, or an indirect action-for example through regulation of a different splicing factor. Hence two series of studies were used to follow-up the finding from the "correlative" Affymetrix exon junction array. A heuristic bioinformatic algorithm was developed to search for YCAY elements within this set of Nova targets, revealing an enrichment of elements within them (although the algorithm was limited, with -50% false positive rate, in its ability to predict targets de novo) (31).
Surprisingly, a position-dependent action of Nova on these transcripts was also discovered, such that Nova binding elements upstream or within alternative exons correlated with inhibition of exon inclusion, while Nova binding downstream correlated with enhancement of exon inclusion (31). An effort to further strengthen these correlations was made, both by undertaking detailed in vitro splicing assays to provide a mechanistic basis for the positional effects, and analysis of splicing intermediates by RT-PCR, providing evidence for asymmetric actions on splicing intermediates that correlated with the position of the YCAY elements (31).
The heavy use of the word "correlation" in the previous section emphasis what was missing from the microarray and bioinformatic studies-evidence of direct Nova-RNA interaction. Although such evidence was possible on a case-by-case basis, made most persuasively with Nova's action on the GABAA transcript (27,31), it was not possible to undertake such studies, nor develop an entirely compelling description of Nova action, on what begain to approach 100 putative Nova-regulated transcripts. Hence a new approach was needed, and developed in the form of cross-linkimmunoprecipitation (CLIP) (32). CLIP takes advantage of the finding that UV-B irradiation induces covalent complexes between protein-nucleic acids when contact distances are within -1 Å (33). By applying UV-irradiation to acutely dissected mouse brains, Nova-RNA complexes in situ were stabilized, allowing rigorous purification. After purification, removal of the protein with proteinase K, CLIP also established that RNA could be efficiently sequenced, using RNA linker ligation and reverse transcription-PCR. Analysis of 34 transcripts identified independently among the first 340 CLIP targets sequenced revealed that they were enriched in YCAY elements, that 71% encoded neuronal synaptic proteins, and that they included Nova-regulated alternative exons (32). Hence CLIP was established as a genome-wide unbiased means of identifying functional RNA-protein interaction sites.
To broaden the observations made with CLIP, high throughput sequencing (HITS) methods were applied, termed HITS-CLIP, to the study of Nova-RNA interactions in 2008 (34). In these experiments, millions of Novacrosslinked RNA fragments of -50-100 nt were sequenced, and very conservatively winnowed into a pool of 168,632 unique tags mapping across the mouse genome. These validated predicted Nova-regulated alternative exons that had been correlated with Nova by exon junction array and bioinformatic strategies. They also identified new clusters of Nova tags surrounding alternative exons that were in fact predictive of de novo regulated exons, and they confirmed the position-dependent bioinformatic map. Moreover, these studies also identified many previously unknown Nova binding sites. For example, clusters of Nova-RNA tags within 3' UTRs were found in some cases to surround alternative poly (A) sites, and this led to biochemical validation and the discovery that Nova was able to regulate alternative polyadenylation choice in the brain.
These studies were thus able to close the loop on a new approach to genomewide, unbiased discovery of RBP-RNA function. Application of basic biochemical principles to identify high affinity targets, descriptive analysis of RNA variants under conditions of a defined variable, such as a genetic null, and HITS-CLIP to discriminate direct from indirect target transcripts, offers a powerful approach to discovery (35).
Future directions for this approach are several. The wealth of data coming from HITS-CLIP suggests that new bioinformatic approaches will be important in synthesizing information. Indeed, recent studies have demonstrated the use of Bayesian networks to combine data from such datasets as exon junction arrays, HITS-CLIP, and motif analysis to both validate and produce new discovery regarding RBP-RNA interaction (36). The approaches worked out for Nova provide general solutions. A number of other RBPs have now been studied by HITS-CLIP (33,37-41), in efforts that, when combined, may provide the groundwork for development of a true combinatorial map of RNA regulation. Finally, HITS-CLIP analysis has been extended to the study of ternary interactions-between small non-coding RNAs, mRNA and regulatory proteins. This was first established for the mammalian Ago protein, demonstrating that Ago-mRNA crosslinked tags cluster directly over microRNA binding seeds, such that these ternary HITS-CLIP maps could decode sites of miRNA-mRNA interactions on a robust, genome-wide basis (42). Subsequently these studies have been reproduced in C elegans (43) and mammalian tissue culture cells (36), and have begun with other small RNAs (piRNAs) (44). These studies offer the exciting possibilities of both developing better understandings and means of capitalizing upon small RNA regulation of gene expression, and overlaying such maps with those developed with HITS-CLIP analysis of more traditional RBPRNA interactions.
Acknowledgements
This work is an overview of the efforts of a large number of people undertaken over the years; while I have tried to cite the efforts of all, I would especially thank Steven Burley, Ron Buckanovich, Jennifer Darnell, Kate Dredge, Lily Jan, Kirk Jensen, Hal Lewis, Aldo Mele, Kiran Musunuru, Giovanni Stefani, Jernej Ule, Donny Licatalosi, Sung-Wook Chi and Chaolin Zhang for major contributions toward developing the key points in the development of the story told here.

This work was supported by the NIH (R01 NS34389 and NS40955 to RBD) and the Howard Hughes Medical Institute. RBD is an Investigator of the Howard Hughes Medical Institute.

  • 1. Darnell RB, Furneaux HM, Posner JB. Characterization of antigens bound by CSF and serum of a patient with cerebellar degeneration: coexpression in Purkinje cells and tumor lines of neuroectodermal origin. Neurology. 1989;39(Suppl 1):385PMID: 2927647ArticlePubMed
  • 2. Darnell RB, Furneaux HM, Posner JB. Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors. J Neurosci. 1991;11:1224–1230. PMID: 1851215ArticlePubMedPMC
  • 3. McKeever MO, Darnell RB. NAP, a human cerebellar degeneration antigen, is a novel, neuron specific, adaptin family member [abstract]. Soc Neurosci. 1992;Abstr 18, 1092
  • 4. Newman LS, McKeever MO, Okano HJ, Darnell RB. Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein. Cell. 1995;82:773–783. PMID: 7671305ArticlePubMed
  • 5. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A. 1996;93:4529–4536. PMID: 8643438ArticlePubMedPMC
  • 6. Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci. 2001;24:239–262. PMID: 11283311ArticlePubMed
  • 7. Dredge BK, Polydorides AD, Darnell RB. The splice of life: alternative splicing and neurological disease. Nat Rev Neurosci. 2001;2:43–50. PMID: 11253358ArticlePubMed
  • 8. Licatalosi DD, Darnell RB. Splicing regulation in neurologic disease. Neuron. 2006;52:93–101. PMID: 17015229ArticlePubMed
  • 9. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004;4:36–44. PMID: 14708025ArticlePubMed
  • 10. Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol. 2004;16:616–622. PMID: 15342008ArticlePubMed
  • 11. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33:270–298. PMID: 16769417ArticlePubMed
  • 12. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4:1321–1324. PMID: 9809559ArticlePubMed
  • 13. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47:9–17. PMID: 10632096ArticlePubMed
  • 14. Frank MO. Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 2010;in pressArticlePubMedPMC
  • 15. Santomasso BD, Roberts WK, Thomas A, Williams T, Blachere NE, Dudley ME, et al. A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A. 2007;104:19073–19078. PMID: 18045792ArticlePubMedPMC
  • 16. Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron. 1993;11:657–672. PMID: 8398153ArticlePubMed
  • 17. Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A. 1998;95:13254–13259. PMID: 9789075ArticlePubMedPMC
  • 18. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 1985;35:538–543. PMID: 2984600ArticlePubMed
  • 19. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell. 1991;67:325–333. PMID: 1655278ArticlePubMed
  • 20. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008;65:3168–3181. PMID: 18581050ArticlePubMedPMC
  • 21. Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuronspecific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci. 1996;16:1114–1122. PMID: 8558240ArticlePubMedPMC
  • 22. Green R, Ellington AD, Bartel DP, Szostak JW. In vitro genetic analysis: selection and amplification of rare functional nucleic acids. Methods Compan Methods Enzymol. 1991;2:75–86. Article
  • 23. Szostak JW, Ellington AD. In vitro selection of functional RNA sequences. The RNA world. 1993. Woodbury, NY: Cold Spring Harbor Laboratory Press; p. 511–533.
  • 24. Buckanovich RJ, Darnell RB. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol. 1997;17:3194–3201. PMID: 9154818ArticlePubMedPMC
  • 25. Jensen KB, Musunuru K, Lewis HA, Burley SK, Darnell RB. The tetranucleotide UCAY directs the specific recognition of RNA by the Nova K-homology 3 domain. Proc Natl Acad Sci U S A. 2000;97:5740–5745. PMID: 10811881ArticlePubMedPMC
  • 26. Lewis HA, Musunuru K, Jensen KB, Edo C, Chen H, Darnell RB, et al. Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. Cell. 2000;100:323–332. PMID: 10676814ArticlePubMed
  • 27. Dredge BK, Darnell RB. Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. Mol Cell Biol. 2003;23:4687–4700. PMID: 12808107ArticlePubMedPMC
  • 28. Dredge BK, Stefani G, Engelhard CC, Darnell RB. Nova autoregulation reveals dual functions in neuronal splicing. EMBO J. 2005;24:1608–1620. PMID: 15933722ArticlePubMedPMC
  • 29. Darnell RB. Developing global insight into RNA regulation. Cold Spring Harb Symp Quant Biol. 2006;71:321–327. PMID: 17381312ArticlePubMed
  • 30. Ule J, Ule A, Spencer J, Williams A, Hu JS, Cline M, et al. Nova regulates brainspecific splicing to shape the synapse. Nat Genet. 2005;37:844–852. PMID: 16041372ArticlePubMed
  • 31. Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, et al. An RNA map predicting Nova-dependent splicing regulation. Nature. 2006;444:580–586. PMID: 17065982ArticlePubMed
  • 32. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP identifies Novaregulated RNA networks in the brain. Science. 2003;302:1212–1215. PMID: 14615540ArticlePubMed
  • 33. Darnell RB. HITS-CLIP: panoramic views of protein-RNA regulation in living cells. Wiley Interdiscip Rev. 2010;1:266–286. ArticlePubMedPMC
  • 34. Licatalosi DD, Mele A, Fak JJ, Ule J, Kayikci M, Chi SW, et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature. 2008;456:464–469. PMID: 18978773ArticlePubMedPMC
  • 35. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet. 2010;11:75–87. PMID: 20019688ArticlePubMedPMC
  • 36. Zhang C, Frias MA, Mele A, Ruggiu M, Eom T, Marney CB, et al. Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. Science. 2010;329:439–443. PMID: 20558669ArticlePubMedPMC
  • 37. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141:129–141. PMID: 20371350ArticlePubMedPMC
  • 38. König J, Zarnack K, Rot G, Curk T, Kayikci M, Zupan B, et al. iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol. 2010;17:909–915. PMID: 20601959ArticlePubMedPMC
  • 39. Sanford JR, Wang X, Mort M, Vanduyn N, Cooper DN, Mooney SD, et al. Splicing factor SFRS1 recognizes a functionally diverse landscape of RNA transcripts. Genome Res. 2009;19:381–394. PMID: 19116412ArticlePubMedPMC
  • 40. Yeo GW, Coufal NG, Liang TY, Peng GE, Fu XD, Gage FH. An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat Struct Mol Biol. 2009;16:130–137. PMID: 19136955ArticlePubMedPMC
  • 41. Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon YS, et al. Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell. 2009;36:996–1006. PMID: 20064465ArticlePubMedPMC
  • 42. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009;460:479–486. PMID: 19536157ArticlePubMedPMC
  • 43. Zisoulis DG, Lovci MT, Wilbert ML, Hutt KR, Liang TY, Pasquinelli AE, et al. Comprehensive discovery of endogenous Argonaute binding sites in Caenorhabditis elegans. Nat Struct Mol Biol. 2010;17:173–179. PMID: 20062054ArticlePubMedPMC
  • 44. Xu M, Medvedev S, Yang J, Hecht NB. MIWI-independent small RNAs (MSY-RNAs) bind to the RNA-binding protein, MSY2, in male germ cells. Proc Natl Acad Sci U S A. 2009;106:12371–12376. PMID: 19597149ArticlePubMedPMC
Table 1
Representative list of paraneoplastic neurologic disorders
crt-42-125-i001.jpg

*small-cell lung cancer, †paraneoplastic encephalomyelitis, ‡paraneoplastic sensory neuronopathy, §paraneoplastic cerebellar degeneration, ∥central nervous system, gynecological cancer, **collapsing response-mediated protein 5, ††stiff person syndrome, ‡‡N-N-methyl-D-aspaate receptor, §§cancer associated retinopathy, ∥∥neuromuscular junction, ¶¶voltage-gated calcium channel, ***myasthenia gravis, †††lambert-Eaton myasthenic syndrome, ‡‡‡progressive encephalomyelitis with rigidity and myoclonus, §§§limbic encephalopathy.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Identifying the mitochondrial ribosomal protein MRPL13 as an oncogenic RBP that promotes proliferation, migration, and anti-apoptotic effects in esophageal cancer cells
      Yaxi Song, Hui Wang, Shiyao Li, Weili Tao, Chunqing Li, Bin Wang, Caifeng Gong
      Heliyon.2024; : e39546.     CrossRef
    • LARP6 suppresses colorectal cancer progression through ZNF267/SGMS2-mediated imbalance of sphingomyelin synthesis
      Xiaoli Long, Xunhua Liu, Ting Deng, Jianxiong Chen, Jiawen Lan, Sijing Zhang, Miao Zhou, Dan Guo, Jun Zhou
      Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
    • Effect and mechanism of circRNAs in tumor angiogenesis and clinical application
      Luyang Zhao, Yuying Guo, Yaxin Guo, Xiang Ji, Dandan Fan, Chen Chen, Weitang Yuan, Zhenqiang Sun, Zhenyu Ji
      International Journal of Cancer.2022; 150(8): 1223.     CrossRef
    • Widespread autogenous mRNA–protein interactions detected by CLIP-seq
      Thomas H Kapral, Fiona Farnhammer, Weihao Zhao, Zhi J Lu, Bojan Zagrovic
      Nucleic Acids Research.2022; 50(17): 9984.     CrossRef
    • Computational tools to study RNA-protein complexes
      Sneha Bheemireddy, Sankaran Sandhya, Narayanaswamy Srinivasan, Ramanathan Sowdhamini
      Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
    • RNA Regulators in Leukemia and Lymphoma
      Camila Prieto, Michael G. Kharas
      Cold Spring Harbor Perspectives in Medicine.2020; 10(5): a034967.     CrossRef
    • Diverse roles of RNA‐binding proteins in cancer traits and their implications in gastrointestinal cancers
      Kiyoshi Masuda, Yuki Kuwano
      WIREs RNA.2019;[Epub]     CrossRef
    • MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change
      Qianru He, Lini Zhao, Xiaobai Liu, Jian Zheng, Yunhui Liu, Libo Liu, Jun Ma, Heng Cai, Zhen Li, Yixue Xue
      Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
    • KHDRBS3 regulates the permeability of blood–tumor barrier via cDENND4C/miR-577 axis
      Peiqi Wu, Yang Gao, Shuyuan Shen, Yixue Xue, Xiaobai Liu, Xuelei Ruan, Lianqi Shao, Yunhui Liu, Ping Wang
      Cell Death & Disease.2019;[Epub]     CrossRef
    • IDH1 fine-tunes cap-dependent translation initiation
      Lichao Liu, J Yuyang Lu, Fajin Li, Xudong Xing, Tong Li, Xuerui Yang, Xiaohua Shen, Zefeng Wang
      Journal of Molecular Cell Biology.2019; 11(10): 816.     CrossRef
    • Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer
      Samantha Moore, Aino I Järvelin, Ilan Davis, Gareth L Bond, Alfredo Castello
      Current Opinion in Genetics & Development.2018; 48: 112.     CrossRef
    • Graphene Oxide-Facilitated Comprehensive Analysis of Cellular Nucleic Acid Binding Proteins for Lung Cancer
      Zhi Shang, Liqiang Qian, Sha Liu, Xiaomin Niu, Zhi Qiao, Yan Sun, Yan Zhang, Liu-Yin Fan, Xin Guan, Cheng-Xi Cao, Hua Xiao
      ACS Applied Materials & Interfaces.2018; 10(21): 17756.     CrossRef
    • NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer
      Andrew T. Ludlow, Mandy Sze Wong, Jerome D. Robin, Kimberly Batten, Laura Yuan, Tsung-Po Lai, Nicole Dahlson, Lu Zhang, Ilgen Mender, Enzo Tedone, Mohammed E. Sayed, Woodring E. Wright, Jerry W. Shay
      Nature Communications.2018;[Epub]     CrossRef
    • Identification and Analysis of Key Residues in Protein–RNA Complexes
      A. Kulandaisamy, Ambuj Srivastava, Pradeep Kumar, R. Nagarajan, S. Binny Priya, M. Michael Gromiha
      IEEE/ACM Transactions on Computational Biology and Bioinformatics.2018; 15(5): 1436.     CrossRef
    • RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment
      Suntaek Hong
      Journal of Cancer Prevention.2017; 22(4): 203.     CrossRef
    • The expanding universe of ribonucleoproteins: of novel RNA-binding proteins and unconventional interactions
      Benedikt M. Beckmann, Alfredo Castello, Jan Medenbach
      Pflügers Archiv - European Journal of Physiology.2016; 468(6): 1029.     CrossRef
    • NOVA2-mediated RNA regulation is required for axonal pathfinding during development
      Yuhki Saito, Soledad Miranda-Rottmann, Matteo Ruggiu, Christopher Y Park, John J Fak, Ru Zhong, Jeremy S Duncan, Brian A Fabella, Harald J Junge, Zhe Chen, Roberto Araya, Bernd Fritzsch, A J Hudspeth, Robert B Darnell
      eLife.2016;[Epub]     CrossRef
    • Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases
      Magdalena Jazurek, Adam Ciesiolka, Julia Starega-Roslan, Katarzyna Bilinska, Wlodzimierz J. Krzyzosiak
      Nucleic Acids Research.2016; : gkw803.     CrossRef
    • UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis
      Laurence Wurth, Panagiotis Papasaikas, David Olmeda, Nadine Bley, Guadalupe T. Calvo, Santiago Guerrero, Daniela Cerezo-Wallis, Javier Martinez-Useros, María García-Fernández, Stefan Hüttelmaier, Maria S. Soengas, Fátima Gebauer
      Cancer Cell.2016; 30(5): 694.     CrossRef
    • Tumor-promoting function and prognostic significance of the RNA-binding protein T-cell intracellular antigen-1 in esophageal squamous cell carcinoma
      Junichi Hamada, Katsutoshi Shoda, Kiyoshi Masuda, Yuji Fujita, Takuya Naruto, Tomohiro Kohmoto, Yuko Miyakami, Miki Watanabe, Yasusei Kudo, Hitoshi Fujiwara, Daisuke Ichikawa, Eigo Otsuji, Issei Imoto
      Oncotarget.2016; 7(13): 17111.     CrossRef
    • RNA-binding proteins, multifaceted translational regulators in cancer
      Laurence Wurth, Fátima Gebauer
      Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.2015; 1849(7): 881.     CrossRef
    • RNA-binding proteins in neurological diseases
      HuaLin Zhou, Marie Mangelsdorf, JiangHong Liu, Li Zhu, Jane Y Wu
      Science China Life Sciences.2014; 57(4): 432.     CrossRef
    • A versatile assay for RNA-binding proteins in living cells
      Claudia Strein, Anne-Marie Alleaume, Ulrich Rothbauer, Matthias W. Hentze, Alfredo Castello
      RNA.2014; 20(5): 721.     CrossRef
    • RNA-binding proteins in Mendelian disease
      Alfredo Castello, Bernd Fischer, Matthias W. Hentze, Thomas Preiss
      Trends in Genetics.2013; 29(5): 318.     CrossRef
    • Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins
      Alfredo Castello, Bernd Fischer, Katrin Eichelbaum, Rastislav Horos, Benedikt M. Beckmann, Claudia Strein, Norman E. Davey, David T. Humphreys, Thomas Preiss, Lars M. Steinmetz, Jeroen Krijgsveld, Matthias W. Hentze
      Cell.2012; 149(6): 1393.     CrossRef
    • Alternative splicing interference by xenobiotics
      Emanuela Zaharieva, J. Kevin Chipman, Matthias Soller
      Toxicology.2012; 296(1-3): 1.     CrossRef
    • Neural antigen‐specific autoimmune disorders
      Raffaele Iorio, Vanda A. Lennon
      Immunological Reviews.2012; 248(1): 104.     CrossRef
    • Paraneoplastic encephalomyelopathies: pathology and mechanisms
      Andrew McKeon, Sean J. Pittock
      Acta Neuropathologica.2011; 122(4): 381.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      RNA Regulation in Neurologic Disease and Cancer
      Cancer Res Treat. 2010;42(3):125-129.   Published online September 30, 2010
      DOI: https://doi.org/10.4143/crt.2010.42.3.125
      Close
    • XML DownloadXML Download
    RNA Regulation in Neurologic Disease and Cancer
    RNA Regulation in Neurologic Disease and Cancer

    Representative list of paraneoplastic neurologic disorders

    *small-cell lung cancer, †paraneoplastic encephalomyelitis, ‡paraneoplastic sensory neuronopathy, §paraneoplastic cerebellar degeneration, ∥central nervous system, gynecological cancer, **collapsing response-mediated protein 5, ††stiff person syndrome, ‡‡N-N-methyl-D-aspaate receptor, §§cancer associated retinopathy, ∥∥neuromuscular junction, ¶¶voltage-gated calcium channel, ***myasthenia gravis, †††lambert-Eaton myasthenic syndrome, ‡‡‡progressive encephalomyelitis with rigidity and myoclonus, §§§limbic encephalopathy.
    Table 1 Representative list of paraneoplastic neurologic disorders

    *small-cell lung cancer, †paraneoplastic encephalomyelitis, ‡paraneoplastic sensory neuronopathy, §paraneoplastic cerebellar degeneration, ∥central nervous system, gynecological cancer, **collapsing response-mediated protein 5, ††stiff person syndrome, ‡‡N-N-methyl-D-aspaate receptor, §§cancer associated retinopathy, ∥∥neuromuscular junction, ¶¶voltage-gated calcium channel, ***myasthenia gravis, †††lambert-Eaton myasthenic syndrome, ‡‡‡progressive encephalomyelitis with rigidity and myoclonus, §§§limbic encephalopathy.

    Table 1

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP